Allogene Therapeutics Stock Target Price and Analyst Consensus
| ALLO Stock | USD 3.04 0.33 9.79% |
The current analyst and expert consensus on Allogene Therapeutics is Strong Buy with 4 hold recommendations. The current projected Allogene Therapeutics target price consensus is 17.64 with 16 analyst opinions. One of the most common ways Allogene Therapeutics analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Allogene Therapeutics vendors, executives, and/or customers. Allogene Therapeutics recommendation module provides expert sentiment on the projected Allogene Therapeutics target price to derive its highest and lowest estimates based on target price standard deviation of 0.0. Check out Macroaxis Advice on Allogene Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
Lowest Forecast 16.05 | Highest Forecast 19.58 | Target Price 17.64 |
Allogene |
It's important to approach Allogene Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Allogene Therapeutics price targets
Allogene Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Allogene Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Allogene Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Allogene Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Allogene Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Allogene Therapeutics is a key component of Allogene Therapeutics valuation and have some predictive power on the future returns of a Allogene Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Allogene Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Impulse Invested over 100 shares | |
 | Dividend Beast Invested over 60 shares | |
 | Business Services Invested few shares | |
 | FinTech Invested over 40 shares | |
 | Investor Favorites Invested over 40 shares | |
 | Macroaxis Picks Invested over 40 shares | |
 | Blockchain Invested few shares | |
 | Synthetics Invested over 100 shares | |
 | Chemicals Makers Invested over 500 shares |
Check out Macroaxis Advice on Allogene Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Transaction History View history of all your transactions and understand their impact on performance |
The data published in Allogene Therapeutics' official financial statements usually reflect Allogene Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Allogene Therapeutics. For example, before you start analyzing numbers published by Allogene accountants, it's critical to develop an understanding of what Allogene Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Allogene Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Allogene Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Allogene Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Allogene Therapeutics. Please utilize our Beneish M Score to check the likelihood of Allogene Therapeutics' management manipulating its earnings.